Clinical Trials Now Enrolling


SONODYNAMIC THERAPY IN DIPG

A Phase 1/2 research study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in DIPG patients.

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT05123534 to view inclusion criteria and additional study details.


AZD1390 FOR RECURRENT GLIOBLASTOMA

A Phase 0/1b clinical trial to evaluate AZD1390 in patients with recurrent glioblastoma.

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT05182905 to view inclusion criteria and additional study details.

Trial Eligibility

NIRAPARIB FOR NEWLY DIAGNOSED GLIOBLASTOMA

A  Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with newly diagnosed glioblastoma.

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT05076513 to view inclusion criteria and additional study details.

Trial Screening

NIRAPARIB FOR RECURRENT GLIOMA (GRADES II-IV)

A  Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with recurrent WHO Grade II, III, or IV glioma with IDH1 or IDH2 mutation and ATRX loss.

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT05076513 to view inclusion criteria and additional study details.

Trial Screening

SONODYNAMIC THERAPY IN RECURRENT HIGH-GRADE GLIOMA

A Phase 0 research study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in recurrent high-grade glioma patients

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04559685 to view inclusion criteria and additional study details.

Trial Screening

PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration and tumor effects.

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04614909 to view inclusion criteria and additional study details.

Trial Screening

INFIGRATINIB FOR RECURRENT HIGH-GRADE GLIOMA

A Phase 0 study of infigratinib in recurrent high-grade glioma patients with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04424966 to view inclusion criteria and additional study details.

Trial Screening Physician Information


ABEMACICLIB PLUS LY3214996 FOR RECURRENT GLIOBLASTOMA

A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma patients scheduled for resection to evaluate central nervous system (CNS) penetration

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04391595 to view inclusion criteria and additional study details.

Trial Screening Physician Information


RIBOCICLIB FOR RECURRENT GLIOBLASTOMA

A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade glioma patients scheduled for resection


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.

Trial Screening

RIBOCICLIB FOR RECURRENT MENINGIOMA

A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade meningioma patients scheduled for resection


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.

Trial Screening